Penumbra PEN Neuro — Revenue
Discontinued — last reported Q3 '23
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Penumbra’s 10-Q, filed November 2, 2023, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's neuro — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's neuro — revenue?
- Penumbra (PEN) reported neuro — revenue of $171.41M in Q3 2023.
- How has Penumbra's neuro — revenue changed year-over-year?
- Penumbra's neuro — revenue increased by 38.9% year-over-year, from $123.36M to $171.41M.
- What does neuro — revenue mean?
- The total revenue earned from selling neurovascular medical devices to healthcare providers.
- How do you interpret neuro — revenue?
- An increase indicates growing clinical adoption and market share for neurovascular products, while a decrease may signal increased competition or a slowdown in neurovascular procedure volumes.
- How does neuro — revenue compare across companies?
- Comparable to neurovascular or specialized medical device revenue segments reported by competitors like Stryker, Medtronic, or MicroPort Scientific.